METHOD OF DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION Russian patent published in 2024 - IPC G01N33/68 G01N30/72 

FIELD: medicine; cardiology.

SUBSTANCE: invention can be used for the diagnosis of chronic heart failure with preserved ejection fraction (CHFpEF). Using quantitative chromatography-mass spectrometric analysis in blood plasma, the concentration of the following metabolites is determined: long-chain acylcarnitine C16:1, amino acid arginine, asymmetric dimethylarginine (ADMA), trimethylamine oxide (TMAO), anthranilic acid, kynurenine, neopterin and 2 metabolite ratios, namely the arginine/ADMA ratio, the kynurenine/tryptophan ratio. Then the value of the estimated parameter P is calculated using the formula Where

Z = -32.636 - 31.380× C1 - 0.232× C2+24.914× C3+0.475× C4+0.049× R1+0.349× C5+0.025× C6+0.146× S7+618.859× R2,

where P is the probability of having CHF, e is the base of the natural logarithm, C1 is the concentration of acylcarnitine C16:1 in mcM; C2 is arginine in mcM, C3 is ADMA in mcM, C4 is TMAO in mcM, C5 is anthranilic acid concentration in mcM, C6 is kynurenine in mcM, C7 is neopterin in mcM, R1 is arginine/ADMA concentration ratio, R2 is concentration ratio kynurenine/tryptophan. If the P value is greater than or equal to 64.7%, it is concluded that CHFpEF is present. When P is less than 64.7%, it is concluded that there is a low probability of having CHFpEF.

EFFECT: method makes it possible to diagnose HFpEF through screening detection of HFpEF in Caucasian patients using biostatistical processing of the results of quantitative determination of isolated blood plasma metabolites.

1 cl, 2 dwg, 2 tbl, 2 ex